<SEC-DOCUMENT>0001140361-22-024127.txt : 20220627
<SEC-HEADER>0001140361-22-024127.hdr.sgml : 20220627
<ACCEPTANCE-DATETIME>20220627160539
ACCESSION NUMBER:		0001140361-22-024127
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220627
FILED AS OF DATE:		20220627
DATE AS OF CHANGE:		20220627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Holdings plc
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39992
		FILM NUMBER:		221044561

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10039056_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">For the Month of June 2022</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39992</div>
      <div>&#160;</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">Immunocore Holdings plc</div>
      <div style="text-align: center; font-weight: bold;">(Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">92 Park Drive</div>
      <div style="text-align: center; font-weight: bold;">Milton Park</div>
      <div style="text-align: center; font-weight: bold;">Abingdon, Oxfordshire OX14 4RY</div>
      <div style="text-align: center; font-weight: bold;">United Kingdom</div>
      <div style="text-align: center; font-weight: bold;">&#160;(Address of principal executive office)</div>
      <div>&#160;</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; width: 25%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div> <br>
      </div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div>&#9746;&#160; Form 20-F&#160; &#160; &#9744;&#160; Form 40-F</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160; &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160; &#9744;</div>
      <div>&#160;</div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;">Press Release</div>
      <div>&#160;</div>
      <div style="text-align: justify;">On June 25, 2022, Immunocore Holdings plc (the &#8220;Company&#8221;) announced that it presented initial data from its first-in-human clinical trial of IMC-I109V at the International Liver Congress hosted by the European
        Association for the Study of the Liver. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 6-K.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">This Report on Form 6-K, including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the Company&#8217;s registration statement on Form F-3ASR (File No. 333-264105) and the Company&#8217;s registration
        statements on Form S-8 (File Nos. 333-226457 and 333-265000) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf0c63a114f144ea5adcd94dbccd1f649" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; font-weight: bold;">No.</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">&#160;</td>
            <td style="width: 2%; vertical-align: middle;">&#160;</td>
            <td style="width: 90%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">
              <div><a href="brhc10039056_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Press Release dated June 25, 2022.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z6d08406cf01842b9ae940724c6aa73cf" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.95%; vertical-align: top;">&#160;</td>
            <td style="width: 45.95%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">
              <div style="font-weight: bold;">IMMUNOCORE HOLDINGS <font style="color: rgb(0, 0, 0);">PLC</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.95%; vertical-align: middle;">&#160;</td>
            <td style="width: 45.95%; vertical-align: middle;">&#160;</td>
            <td style="width: 4.96%; vertical-align: bottom;">&#160;</td>
            <td style="vertical-align: bottom;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3.95%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">Date:</div>
            </td>
            <td style="width: 45.95%; vertical-align: bottom; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">June 27, 2022</div>
            </td>
            <td style="width: 4.96%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div>/s/ <font style="color: rgb(0, 0, 0);">Bahija Jallal, Ph.D.</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.95%; vertical-align: top;">&#160;</td>
            <td style="width: 45.95%; vertical-align: top;">&#160;</td>
            <td style="width: 4.96%; vertical-align: top;">&#160;</td>
            <td style="width: 4.96%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 39.98%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Bahija Jallal, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3.95%; vertical-align: top;">&#160;</td>
            <td style="width: 45.95%; vertical-align: top;">&#160;</td>
            <td style="width: 4.96%; vertical-align: top;">&#160;</td>
            <td style="width: 4.96%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 39.98%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10039056_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.4.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font></div>
  <div style="text-align: right;"><br>
  </div>
  <div style="text-align: right;"><img src="image00002.jpg"></div>
  <div style="text-align: center;"><br>
  </div>
  <div style="text-align: center;"><img width="802" border="0" height="2" src="image00001.jpg"></div>
  <div><br>
  </div>
  <div>
    <div style="color: rgb(10, 65, 78); font-style: italic; font-weight: bold;">PRESS RELEASE</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(9, 71, 110); font-weight: bold;">Immunocore announces the presentation of initial data from the Phase 1 ImmTAV&#174; trial for chronic Hepatitis B at the EASL International Liver Congress&#8482;</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;">IMC-I109V, T cell receptor bispecific, targets an envelope antigen</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman'; font-style: italic;">Single Ascending Dose portion of Phase 1 study to evaluate safety,</font><font style="font-family: 'Times New Roman';">&#160;</font><font style="font-family: 'Times New Roman'; font-style: italic;">antiviral activity, and pharmacokinetics</font></div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;">In the initial cohort, HBsAg declines and ALT elevations indicated that a single, very low dose of IMC-I109V elicited on-target activity, consistent with mechanism of action and without any adverse
      events</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: justify;">(OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md., US, 25 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) (&#8220;Immunocore&#8221; or the &#8220;Company&#8221;), a commercial-stage biotechnology company pioneering the
        development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced that initial data from the first three patients in
        the first-in-human clinical trial of IMC-I109V was presented at the EASL International Liver Congress in London, UK.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">IMC-I109V is a TCR bispecific designed to specifically eliminate HBV-infected hepatocytes expressing hepatitis B surface antigen (HBsAg) via T cell redirection. IMC-I109V is designed to overcome T cell dysfunction by
        recruiting non-exhausted T cells to eliminate hepatocytes harbouring covalently closed circular DNA or integrated HBV DNA. Elimination of these cells is necessary to achieve a state of &#8216;functional cure&#8217; defined as sustained HBsAg loss in addition
        to undetectable HBV DNA 6 months post-treatment. Since the mechanism results in hepatocyte lysis, transient liver enzyme increases are expected, necessitating a conservative dosing schedule in the Company&#8217;s first-in-human study of IMC-I109V.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">In this first cohort, three patients each received a single dose of 0.8 mcg, based on the minimum anticipated biological effect level (MABEL). The dose in this initial cohort was well tolerated and was not associated
        with adverse events were reported in any patient. The maximum serum concentrations of IMC-I109V were consistent with the dose level. By hour 12, serum concentrations declined below the lower limit of quantification. IL-6 cytokine levels increased
        within the first 24 hours in all three patients, which is consistent with the IMC-I109V mechanism of action. Small and transient increases in alanine transaminase (ALT), albeit within the normal range, were observed in the first few days after
        dosing, before returning to normal levels. In two of the three patients, serum HBsAg levels transiently decreased, with the same kinetics as ALT, by 11-15% during Days 3-15 post infusion, before returning to baseline within 3 weeks post-infusion.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">&#8220;We designed our T cell receptor based bispecific proteins to harness the immune system to potentially achieve a functional cure for HBV,&#8221; <font style="font-weight: bold;">said David Berman, Head of Research &amp;
          Development at Immunocore</font>. &#8220;Although only a few patients received a single, very low dose of IMC-I109V, we are very encouraged by our observations of transient decrease in HBV surface antigen, as well as transient elevations in ALT and
        cytokines, which match the profile we had hypothesized based on the IMC-I109V mechanism of action. We look forward to enrolling more patients at higher doses in the Phase 1 program.&#8221;</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td rowspan="1" style="width: 100%; font-size: 8pt;">
                  <div style="text-align: center;"><img src="image00003.jpg"></div>
                  <div><br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 100%; font-size: 8pt;">
                  <div style="text-align: right; color: rgb(9, 71, 110);">Immunocore Holdings plc, 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK</div>
                  <div style="text-align: right; color: rgb(9, 71, 110);">T: +44 (0)1235 438600&#160; |&#160; www.immunocore.com</div>
                  <div style="text-align: right; color: rgb(9, 71, 110);">Registered in England no: 6456207&#160; |&#160; VAT No. GB 939 6694 55</div>
                </td>
              </tr>

          </table>
        </div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify;">The trial is an open label study evaluating the safety, antiviral activity, and pharmacokinetics of IMC-I109V in HLA-A*02:01 positive patients with chronic hepatitis B who are non-cirrhotic, HBeAg-negative and
        virally suppressed on nucleos(t)ide analogues. Part 1 is a single ascending dose to identify a safe and pharmacologically active dose. Part 2 is a multiple ascending dose to evaluate safety and anti-HBV activity of repeated doses over 24 weeks.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;###</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">About ImmTAV molecules and infectious diseases</div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">ImmTAV (Immune mobilising monocolonal TCRs Against Virus) molecules are novel bispecific molecules that, like ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) molecules, are designed to
        enable the immune system to recognize and eliminate virally infected cells.</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">Immunocore is advancing clinical candidates to cure patients with HIV and HBV. The Company aims to achieve a reduction in viral reservoirs to enable sustained control of HIV after stopping
        antiretroviral therapy (ART), without the risk of virological relapse or onward transmission. This is known as &#8216;functional cure&#8217;. For the treatment of HBV, the Company aims to achieve sustained loss of circulating viral antigens and markers of
        viral replication after stopping medication for people living with chronic hepatitis B.</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">About Immunocore</div>
    <div>Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; Immune mobilizing monoclonal TCRs Against X disease &#8211; designed to treat a broad range of diseases,
      including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and
      infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore&#8217;s most advanced oncology TCR therapeutic, KIMMTRAK (tebentafusp-tebn), has been approved by the U.S. FDA for the treatment
      of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to
      be insensitive to other immunotherapies.</div>
    <div> <br>
    </div>
    <div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 100%;">
                  <div style="text-align: left; color: rgb(9, 71, 110); font-size: 8pt;">Page <font id="DSPFPageNumber">2</font> of 3</div>
                </td>
              </tr>

          </table>
        </div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Forward Looking Statements</div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor
          provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to,
          statements regarding: the therapeutic potential of </font><font style="font-family: 'Times New Roman';">IMC-I109V<font style="color: rgb(0, 0, 0);"> to be an effective treatment for patients with HBV; the expected clinical benefits of </font>IMC-I109V<font style="color: rgb(0, 0, 0);"> including its potential as a &#8220;functional cure&#8221;; anticipated results from the Phase 2 portion of the clinical trial of </font>IMC-I109V<font style="color: rgb(0, 0, 0);"> and expectations regarding the ability to
            recruit and enroll additional patients in the clinical trial of </font>IMC-I109V<font style="color: rgb(0, 0, 0);">. Any forward-looking statements are based on management&#8217;s current expectations of future events and are subject to a number of
            risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company&#8217;s control. These risks and uncertainties
            include, but are not limited to, the impact of the ongoing COVID-19 pandemic and the Omicron variant on the Company&#8217;s business, strategy clinical trials and financial position; Immunocore&#8217;s ability to maintain regulatory approval of KIMMTRAK;
            its ability to execute its commercialization strategy for KIMMTRAK including the timing or likelihood of expansion into additional markets or geographies; its ability to develop, manufacture and commercialize its other product candidates;
            commercial supply of KIMMTRAK or any future approved products, and launching, marketing and selling of KIMMTRAK or any future approved products; Immunocore&#8217;s ability and plans in continuing to establish and expand a commercial infrastructure
            and to successfully launch, market and sell KIMMTRAK in the United States, European Union and other territories; that positive results from earlier pre-clinical studies of Immunocore&#8217;s product candidates may not necessarily be predictive of the
            results from required later pre-clinical studies and future clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore&#8217;s ability to obtain,
            maintain and enforce intellectual property protection for KIMMTRAK or any product candidates it is developing; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or
            enrollment rates that are lower than expected; changes in expected or existing competition; and the success of Immunocore&#8217;s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are
            described in greater detail in the section titled "Risk Factors" in Immunocore&#8217;s filings with the Securities and Exchange Commission, including Immunocore&#8217;s most recent Annual Report on Form 20-F for the year ended December 31, 2021 filed with
            the Securities and Exchange Commission on March 3, 2022, as well as discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s subsequent filings with the Securities and Exchange Commission. All information in
            this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.</font></font></div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="font-weight: bold;">CONTACT:</div>
      <div>&#160;</div>
    </div>
    <div style="color: rgb(0, 0, 0); font-weight: bold;">Immunocore</div>
    <div style="color: rgb(0, 0, 0);">Debra Nielsen, Head of Communications</div>
    <div>T: +1 (610) 368-8602</div>
    <div>E: debra.nielsen@immunocore.com</div>
    <div>Follow on Twitter: @Immunocore</div>
    <div><br>
    </div>
    <div style="color: rgb(0, 0, 0); font-weight: bold;">Consilium Strategic Communications (corporate and financial)</div>
    <div style="color: rgb(0, 0, 0);">Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson</div>
    <div>T: +44 (0)203 709 5700</div>
    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">E: </font><u><font style="font-size: 10pt; font-family: 'Times New Roman';">Immunocore@consilium-comms.com</font></u></div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Investor Relations</div>
    <div>Clayton Robertson, Head of Investor Relations</div>
    <div>T: +1 215-384-4781</div>
    <div>E: ir@immunocore.com</div>
    <div><br>
    </div>
    <div><font style="color: rgb(0, 0, 0);"> </font><br>
      <div id="DSPFPageFooter" style="width: 100%;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 100%;">
                <div style="text-align: left; color: rgb(9, 71, 110); font-size: 8pt;">Page <font id="DSPFPageNumber">3</font> of 3</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  " R(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#OZ***_$3]
M!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#UW0_^0+I__7O'_P"@BBBBOV?"_P &'HOR/@JW
&\27JS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !( 2$# 2(  A$! Q$!_\0
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJVI<:==8_YY/_(UYO\
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MI:** #&>M   P  /0444 (RJZE7 92,$$9!J&"SMH'WP6\,;=,I&%/Z5/10
M4444 036=M.^Z>WAD;IET#']:F1510J*%4#  & *6B@ J&>UM[@@W$$4I'0N
M@;'YU-10 V.-(HPD2*B#HJC %.//6BB@!% 484 #T%+110 BHJ@A5 !ZX&*;
MY,?_ #S3_OD4^B@!GDQ_\\T_[Y%/  & ,"BB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  ! R(# 2(  A$! Q$!_\0
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M]=6_F:K445]$MCYE[A1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [O3O^0?:_]<E_D****P9U
$+8__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
